Company Overview and News

39
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

24m zacks
Chicago, IL – June 22, 2018 – Today, Zacks Investment Ideas feature highlights Features: CRISPR Therapeutics (CRSP - Free Report) , Editas Medicine (EDIT - Free Report) andIntellia Therapeutics (NTLA - Free Report) .
NTLA EDIT MS.PRI MS.PRK MPX MS.PRE CRSP MS.PRF MS.PRG MS MS.PRA FIVE

169
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

2018-06-21 seekingalpha
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW

32
CRISPR Science and Stocks: Knowing Enough to Invest

2018-06-20 zacks
By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.
NTLA EDIT IP GILD INPAP CRSP

11
UCal and Partners Win U.S. Patent Related to CRISPR-Cas9

2018-06-20 genengnews
The Regents of the University of California (UC), the University of Vienna, and Emmanuelle Charpentier, Ph.D., of the Max-Planck Institute in Berlin, have been granted U.S. Patent No. 10,000,772 for intellectual property related to CRISPR/Cas9 genome editing technology. [Genetic Literacy Project]
NTLA CRSP

11
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

2018-06-19 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.
NTLA VRTX CRSP

81
Gilead Oncology CAR T-Cell Therapies Outlook Compelling

2018-06-18 seekingalpha
If cell therapies are curative, new business models will become more cyclical. Harvoni and Sovaldi cure rates exceeding 90% show Gilead understands this new paradigm.
VYGR BOLD NTLA ATRA EDIT GILD CRSP ABEO ABEOW ONCE

129
The Case for Adding Low-Fee Asset Classes to a Diversified Portfolio

2018-06-15 investorplace
Investors can easily create a stock and bond “set-and-forget-it,” diversified, lazy exchange-traded fund (ETF) portfolio — then kick back and relax. But what if you want more than just the typical stock and bond ETFs in your affordable investment portfolio? There’s a case to be made for traveling off the beaten ETF path. Consider adding alternative asset classes — commodities, sector bets, smart beta funds and more — without breaking the bank.
PCG NTLA F MS.PRE MS.PRF MS.PRG ILMN MS.PRA MS.PRI MU GM.WS.A MS.PRK GM.WS.B GM.WS.C MS GM GM.WSB

26
Think Twice Before Divesting In Crispr Amid Cancer Concerns

2018-06-15 seekingalpha
Two publications released Monday morning suggest CRISPR-Cas9 editing may lead to systematic propagation of cancer-prone cells.
NTLA EDIT CRSP

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

25
Crispr Therapeutics Down On Cancer Concerns - Unjustified Market Reaction?

2018-06-12 seekingalpha
Two reports in Nature and one interpretation of a STAT News report have taken the three CRISPR stocks down.
NTLA EDIT CRSP

37
Crispr Therapeutics: Beware Of Articles Minimizing The Clinical Hold Risk

2018-06-11 seekingalpha
Articles published last week appear to be examples of confirmation bias showing too little regard for the potential risk factors associated with CRISRP editing.
NTLA VRTX EDIT BLUE CRSP BLUE

11
CRISPR Therapeutics' stock tumbles after report that edited genes might seed tumors - MarketWatch

2018-06-11 marketwatch
Shares of CRISPR Therapeutics AG CRSP, -12.65% tumbled 12% in active midday trade Monday, after a STAT report that edited cells might cause cancer. Volume spiked to 3.1 million shares, already nearly double the full-day average of about 1.7 million shares. CRISPR Therapeutics is a gene editing company that develops treatments for serious diseases using its proprietary CRISPR/Cas9 platform, which allow precise and directed changes to genomic DNA.
NTLA CRSP

11
Should You Invest in the ARK Innovation ETF (ARKK)?

2018-06-06 zacks
Looking for broad exposure to the Technology - Broad segment of the U.S. equity market? You should consider the ARK Innovation ETF (ARKK - Free Report) , a passively managed exchange traded fund launched on 10/31/2014.
NTLA SSYS AMZA ARKK

165
Crispr On Hold While Sangamo Accelerates

2018-06-04 seekingalpha
The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week.
NTLA AVXS CRSP ABEO ONCE RGNX VYGR BOLD EDIT CELG NVS BLUE ABEOW PFE

54
The Zacks Analyst Blog Highlights: AAC Holdings, Bryn Mawr Bank, Lindblad Expeditions Holdings, Orchid Island Capital and Salem Media Group

2018-06-04 zacks
Chicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AAC Holdings, Inc. (AAC - Free Report) , Bryn Mawr Bank Corporation (BMTC - Free Report) , Lindblad Expeditions Holdings, Inc. (LIND - Free Report) , Orchid Island Capital, Inc.
NTLA LINDW DB UAA JBLU CLAC ORC AAC UA BRK.A CLACW DG CLACU BMTC LIND SALM

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 45826J105